ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 992,87
0,18%
Dow Jones
38 686,32
1,51%
DAX
18 497,94
-0,09%
Brent Oil
81,295
0,00%
Bitcoin
67 668,83
-0,08%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Viracta Therapeutics Inc (VIRX)

  7. Viracta Therapeutics Inc (VIRX) Actualités

VIRX

Viracta Therapeutics (VIRX)

Viracta Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:VIRX
DateHeureSourceTitreSymboleSociété
31/05/202422h46Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:VIRXViracta Therapeutics Inc
30/05/202401h12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
17/05/202422h05GlobeNewswire Inc.Viracta Therapeutics Announces New Employment Inducement GrantsNASDAQ:VIRXViracta Therapeutics Inc
16/05/202422h23Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:VIRXViracta Therapeutics Inc
14/05/202413h00GlobeNewswire Inc.Viracta Therapeutics Appoints Michael Faerm as Chief Financial OfficerNASDAQ:VIRXViracta Therapeutics Inc
09/05/202423h04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:VIRXViracta Therapeutics Inc
09/05/202422h05GlobeNewswire Inc.Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
07/05/202422h05GlobeNewswire Inc.Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare ConferenceNASDAQ:VIRXViracta Therapeutics Inc
15/04/202414h00GlobeNewswire Inc.Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell LymphomaNASDAQ:VIRXViracta Therapeutics Inc
01/04/202414h30GlobeNewswire Inc.Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of TaiwanNASDAQ:VIRXViracta Therapeutics Inc
07/03/202423h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:VIRXViracta Therapeutics Inc
07/03/202422h19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:VIRXViracta Therapeutics Inc
07/03/202422h05GlobeNewswire Inc.Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
29/02/202414h00GlobeNewswire Inc.Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 TrialNASDAQ:VIRXViracta Therapeutics Inc
28/02/202402h40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:VIRXViracta Therapeutics Inc
14/02/202403h04Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:VIRXViracta Therapeutics Inc
06/02/202422h05GlobeNewswire Inc.Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:VIRXViracta Therapeutics Inc
04/01/202414h00GlobeNewswire Inc.Viracta Therapeutics Provides Clinical Update and Outlook for 2024NASDAQ:VIRXViracta Therapeutics Inc
12/12/202314h00GlobeNewswire Inc.Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal CarcinomaNASDAQ:VIRXViracta Therapeutics Inc
04/12/202314h30GlobeNewswire Inc.Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose LevelsNASDAQ:VIRXViracta Therapeutics Inc
09/11/202314h30GlobeNewswire Inc.Viracta Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
07/11/202322h15GlobeNewswire Inc.Viracta Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:VIRXViracta Therapeutics Inc
04/10/202313h00GlobeNewswire Inc.Viracta Therapeutics to Host R&D Day Highlighting Nana-val in Epstein-Barr Virus (EBV)-Associated CancersNASDAQ:VIRXViracta Therapeutics Inc
05/09/202315h00GlobeNewswire Inc.Viracta Therapeutics to Host R&D Day on October 4, 2023NASDAQ:VIRXViracta Therapeutics Inc
18/08/202322h05GlobeNewswire Inc.Viracta Therapeutics Announces New Employment Inducement GrantNASDAQ:VIRXViracta Therapeutics Inc
14/08/202314h00GlobeNewswire Inc.Viracta Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:VIRXViracta Therapeutics Inc
08/08/202314h30GlobeNewswire Inc.Viracta Therapeutics Announces Publication in Blood Advances Demonstrating Promising and Durable Signal of Nana-val Efficacy in Patients with Relapsed or Refractory (R/R) Epstein-Barr Virus-Positive (EBV+) LymphomaNASDAQ:VIRXViracta Therapeutics Inc
07/08/202313h30GlobeNewswire Inc.Viracta Therapeutics Appoints Darrel P. Cohen, M.D., Ph.D. as Chief Medical OfficerNASDAQ:VIRXViracta Therapeutics Inc
28/06/202314h00GlobeNewswire Inc.Viracta Therapeutics’ Pivotal NAVAL-1 Trial Achieves Efficacy Threshold for Expansion in Relapsed or Refractory EBV-positive Peripheral T-Cell Lymphoma (R/R EBV+ PTCL)NASDAQ:VIRXViracta Therapeutics Inc
10/06/202300h50Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:VIRXViracta Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:VIRX

Dernières Valeurs Consultées

EU
VK
Vallourec
EU
PX4
SBF 120
NASDAQ
GOOGL
Alphabet
NASDAQ
MSFT
Microsoft
NYSE
DIS
Walt Disney
EU
SGO
Cie de SaintGobain
EU
LR
Legrand
EU
DG
Vinci
EU
ML
Michelin
EU
HO
Thales
FTSE
UKX
FTSE 100
EU
CS
Axa
EU
RNO
Renault
COIN
BTCUSD
Bitcoin
NASDAQ
AMZN
Amazon.com
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés